These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 17469682)
1. The role of functional assessment as an outcome measure in antidementia treatment. Massoud F Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S47-51. PubMed ID: 17469682 [TBL] [Abstract][Full Text] [Related]
2. Global assessment measures for assessing efficacy in dementia drug trials. Rockwood K Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S52-6. PubMed ID: 17469683 [TBL] [Abstract][Full Text] [Related]
3. Target symptoms and outcome measures: cognition. Kirk A Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S42-6. PubMed ID: 17469681 [TBL] [Abstract][Full Text] [Related]
4. Quality of life in dementia. Naglie G Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S57-61. PubMed ID: 17469684 [TBL] [Abstract][Full Text] [Related]
6. Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment. Desai AK; Grossberg GT; Sheth DN CNS Drugs; 2004; 18(13):853-75. PubMed ID: 15521790 [TBL] [Abstract][Full Text] [Related]
7. Global measures: utility in defining and measuring treatment response in dementia. Reisberg B Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic issues in vascular dementia: studies, designs and approaches. Black SE Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S125-30. PubMed ID: 17474183 [TBL] [Abstract][Full Text] [Related]
9. Restriction in complex activities of daily living in MCI: impact on outcome. Hussain H Neurology; 2007 May; 68(18):1544-5; author reply 1545. PubMed ID: 17470764 [No Abstract] [Full Text] [Related]
10. Disease staging and milestones. Rabheru K Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S62-6. PubMed ID: 17469685 [TBL] [Abstract][Full Text] [Related]
15. Differential cognitive deterioration in dementia: a two year longitudinal study. Chamberlain SR; Blackwell AD; Nathan PJ; Hammond G; Robbins TW; Hodges JR; Michael A; Semple JM; Bullmore ET; Sahakian BJ J Alzheimers Dis; 2011; 24(1):125-36. PubMed ID: 21206003 [TBL] [Abstract][Full Text] [Related]
16. Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Kornhuber J; Schmidtke K; Frolich L; Perneczky R; Wolf S; Hampel H; Jessen F; Heuser I; Peters O; Weih M; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Seuchter SA; Rüther E; Henn F; Maier W; Wiltfang J Dement Geriatr Cogn Disord; 2009; 27(5):404-17. PubMed ID: 19339779 [TBL] [Abstract][Full Text] [Related]
17. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration. Rozzini L; Chilovi BV; Conti M; Bertoletti E; Delrio I; Trabucchi M; Padovani A Int J Geriatr Psychiatry; 2007 Dec; 22(12):1217-22. PubMed ID: 17562522 [TBL] [Abstract][Full Text] [Related]
18. Utilization of the Dementia Rating Scale-2 and cognitive enhancers in the diagnosis and treatment of cognitive disorders and dementia. Caston JC; Diehl LA; Hedgepath AW J S C Med Assoc; 2004 Feb; 100(2):32-8. PubMed ID: 15040232 [No Abstract] [Full Text] [Related]
19. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Fariello RG Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984 [No Abstract] [Full Text] [Related]